List of Studies ( Metabolite:Slaframine)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST001788 | AN002899 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | Intensity | |
ST001788 | AN002900 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | Intensity | |
ST002010 | AN003276 | Chemoresistant Ovarian Cancer Global Metabolomics | Cultured cells | Human | Cancer | The University of South Australia | Intensity |
ST000291 | AN000464 | LC-MS Based Approaches to Investigate Metabolomic Differences in the Urine of Young Women after Drinking Cranberry Juice or Apple Juice | Urine | Human | University of Florida | Peak area | |
ST002066 | AN003365 | Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer | Lung | Mouse | Cancer | The Walter and Eliza Hall Institute of Medical Research | peak height |
ST002104 | AN003439 | Chemoresistant Cancer Cell Lines are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations | Cultured cells | Human | Cancer | Future Industries Institute | peak height |
ST002412 | AN003931 | Metabolic effects of the protein kinase R | Macrophages | Mouse | Hudson | peak height | |
ST002698 | AN004372 | Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites | Infected Red Blood Cells | Plasmodium berghei | Malaria | Peter Doherty Institute for Infection and Immunity | peak height |
ST002792 | AN004542 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
ST002926 | AN004799 | Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | peak height |
ST003053 | AN005006 | Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics | Bacterial cells | Staphylococcus aureus | Bacterial infection | Monash University | peak height |
ST003144 | AN005159 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST000414 | AN000655 | Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action | Cells | Plasmodium falciparum | Malaria | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height |
ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST000546 | AN000832 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height |
ST001033 | AN001694 | Determination of mode of action of anti-malalrial drugs using untargeted metabolomics | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak height |
ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST003179 | AN005221 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | Peak height |
ST001201 | AN001998 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001201 | AN001998 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001204 | AN002004 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001204 | AN002004 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001547 | AN002576 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | Peak intensity | |
ST001548 | AN002578 | β-Adrenergic regulation of metabolism in macrophages (part-II) | Macrophages | Human | Monash University | Peak intensity | |
ST001549 | AN002580 | β-Adrenergic regulation of metabolism in macrophages (part-III) | Macrophages | Human | Monash University | Peak intensity | |
ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002107 | AN003446 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST002108 | AN003448 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST002309 | AN003771 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST001304 | AN002172 | Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii | Fibroblast cells | Toxoplasma gondii | Parasitic infection | Monash University | Signal Intensity |
ST001315 | AN002189 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | Signal Intensity |